Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
Authors
Keywords
-
Journal
Scientific Reports
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-07
DOI
10.1038/s41598-021-04075-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study
- (2021) Kosuke Ebina et al. CLINICAL RHEUMATOLOGY
- Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study
- (2021) Yuichi Maeda et al. RHEUMATOLOGY INTERNATIONAL
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-
- (2020) Kosuke Ebina et al. CLINICAL RHEUMATOLOGY
- Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway
- (2020) John Fitton et al. RHEUMATOLOGY
- Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry
- (2020) Nobunori Takahashi et al. Scientific Reports
- Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
- (2019) Masayoshi Harigai et al. Modern Rheumatology
- Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis
- (2019) Christina Charles‐Schoeman et al. Arthritis & Rheumatology
- Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-
- (2019) Kosuke Ebina et al. PLoS One
- Sex and Management of Rheumatoid Arthritis
- (2018) Ennio Giulio Favalli et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis
- (2018) Keiji Hirota et al. IMMUNITY
- Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study-
- (2018) Kosuke Ebina et al. PLoS One
- Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
- (2018) S.-C. Bae et al. ZEITSCHRIFT FUR RHEUMATOLOGIE
- Diagnosis and Management of Rheumatoid Arthritis
- (2018) Daniel Aletaha et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate
- (2018) Jeffrey R Curtis et al. ARTHRITIS CARE & RESEARCH
- Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies
- (2017) Christina Charles-Schoeman et al. JOURNAL OF RHEUMATOLOGY
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan
- (2017) Shunsuke Mori et al. PLoS One
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registry
- (2016) Clément Lahaye et al. RHEUMATOLOGY
- Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry
- (2016) Ennio Giulio Favalli et al. ARTHRITIS CARE & RESEARCH
- Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
- (2016) Fenglong Xie et al. Arthritis & Rheumatology
- Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry
- (2015) Cem Gabay et al. RHEUMATOLOGY
- Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry
- (2015) Tanja Schjødt Jørgensen et al. RHEUMATOLOGY
- Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies
- (2014) E. G. Favalli et al. RHEUMATOLOGY
- Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
- (2014) Stanley Cohen et al. Arthritis & Rheumatology
- Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
- (2013) M Neovius et al. ANNALS OF THE RHEUMATIC DISEASES
- Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan
- (2013) T. Koike et al. JOURNAL OF RHEUMATOLOGY
- A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry
- (2012) Jeffrey D Greenberg et al. ANNALS OF THE RHEUMATIC DISEASES
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) D. Aletaha et al. ANNALS OF THE RHEUMATIC DISEASES
- Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
- (2010) K. L. Hyrich et al. RHEUMATOLOGY
- Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis
- (2009) Sophie Martin Du Pan et al. ARTHRITIS AND RHEUMATISM
- Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
- (2009) Ryuji Koike et al. Modern Rheumatology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now